AbbVie Inc. $ABBV Stock Acquired by Crescent Grove Advisors LLC

Crescent Grove Advisors LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 62.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 7,967 shares of the company’s stock after buying an additional 3,061 shares during the quarter. Crescent Grove Advisors LLC’s holdings in AbbVie were worth $2,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Ranch Capital Advisors Inc. increased its position in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its position in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of AbbVie in the second quarter worth approximately $23,557,000. Wedge Capital Management L L P NC lifted its position in shares of AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares during the last quarter. Finally, State Street Corp lifted its holdings in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ABBV shares. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. JPMorgan Chase & Co. upped their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Wells Fargo & Company increased their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Morgan Stanley lifted their price target on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, BMO Capital Markets upped their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $278.07.

AbbVie Price Performance

Shares of ABBV stock opened at $284.59 on Friday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The company has a market cap of $502.80 billion, a price-to-earnings ratio of 80.39, a PEG ratio of 1.30 and a beta of 0.24. The stock has a 50 day simple moving average of $265.60 and a 200-day simple moving average of $241.46.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.